Respiratory Syncytial Virus (RSV)

This resource provides a detailed overview of Respiratory Syncytial Virus (RSV), highlighting its potential to cause severe infections, hospitalizations, and significant health impacts, particularly among older adults, young children, and individuals with weakened immune systems or chronic health conditions.

RSV can have a substantial impact on the workforce and economy. The estimated market productivity loss per working adult aged 60 and older due to RSV-related deaths ranges from CAD 48,000 to CAD 365,000. This highlights the critical importance of RSV vaccination for adults to reduce these significant economic losses.These statistics demonstrate the broader financial advantages of implementing adult vaccination programs.

Emphasizing preventive measures, such as RSV vaccination, proper hand hygiene, and staying home when sick, can significantly reduce the health and economic burdens associated with RSV. Prioritizing vaccination is essential to protecting vulnerable populations and maintaining productivity.

Refer to the fact sheet below for more information.